HSS(MD) 37 2022 - WORLD PATIENT SAFETY DAY 17 SEPTEMBER 2022

National Institute for Health and Care Excellence (NICE) Covid-19 Rapid Guidance – ~ June 2022

HSS(MD) 45 2022 – TECOVIRIMAT AS A TREATMENT FOR PATIENTS HOSPITALISED DUE TO MONKEYPOX VIRAL INFECTION

HSS(MD) 43 2022 – EUROPEAN MEDICINES AGENCY (EMA) APPROVAL OF COMIRNATY AND SPIKEVAX BIVALENT ORIGINAL / OMICRON BA.1 COVID-19 VACCINES

HSS(MD) 42 2022 – SHINGLES VACCINATION PROGRAMME – ELIGIBILITY CRITERIA

ADDENDUM to HSS(MD) 37/2022- WORLD PATIENT SAFETY DAY 17 SEPTEMBER 2022 EVENTS POSTPONED

NatPSA_P.aeruginosa_contamination_24062022

HSC (SQSD) 16 22 Inadvertent oral administration of potassium permanganate

HSS MD 21 2022 - PERMANENT SUSPENSION OF THE 15 MINUTE WITH COVID-19 VACCINES

HSS MD 20 2022 - COVID-19 TREATMENTS FOR NON-HOSPITALISED PATIENTS

HSS MD 13 2022 COVID-19 SPRING BOOSTER VACCINATION PROGRAMME

HSS MD 9 2022 JCVI UPDATE ON ADVICE FOR PRIMARY COVID-19 VACCINATION OF CHILDREN AGED 5 TO 11 YEARS

HSS MD 2 2022 - MANAGEMENT OF HEALTH AND SOCIAL CARE STAFF WHO ARE CONFIRMED CASES OF COVID-19 - UPDATED GUIDANCE

HSS(MD) 89 2021 - JCVI UPDATE ON ADVICE FOR COVID-19 VACCINATION OF CHILDREN AND YOUNG PEOPLE

Interim Clinical Commissioning Policy: Neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19

HSS(MD) 81 2021 (Addendum) - NEUTRALISING MONOCLONAL ANTIBODIES (nMABs) OR ANTIVIRALS FOR NON-HOSPITALISED PATIENTS WITH COVID-19 – FURTHER ADDENDUM

UPDATED POLICY FOR MANAGEMENT OF SELF-ISOLATION OF CLOSE CONTACTS OF COVID-19 CASES - ADDITIONAL SAFEGUARDS FOR HEALTH AND SOCIAL CARE STAFF

ANNEX A CONTACTS OF COVID-19 CASES - ADDITIONAL SAFEGUARDS FOR HEALTH AND SOCIAL CARE STAFF 21 DECEMBER 2021

HSS(MD) 29 2021 (Addendum) - COVID-19 THERAPEUTIC ALERT – WITHDRAWAL OF THE RECOMMENDATION FOR CONSIDERATION OF INHALED BUDESONIDE AS A TREATMENT OPTION FOR COVID-19

HSS MD 80 2021 VACCINATION ISSUES –COVID-19 VACCINATION PROGRAMME

HSS MD 79 2021 JCVI ISSUES ADVICE ON THE VACCINE RESPONSE TO THE OMICRON VARIANT

HSS(MD) 76 2021 - UPDATE FROM JCVI REGARDING SECOND DOSES FOR 16 AND 17 YEAR OLDS, BOOSTERS FOR 40 TO 49 YEAR OLDS AND TIMING OF THE INTERVAL FOR BOOSTER DOSES

IMMEDIATE ACTIONS IN RESPONSE TO NEW VARIANT SARS-COV-2 IDENTIFIED

HSS(MD) 75 2021 – PATIENTS REQUIRING ASTRAZENECA VACCINE AS A BOOSTER

06_10_2021 Letter to Briege Donaghy RQIA Dysphagia Regional Guidance

HSS MD 69 2021 COVID-19 BOOSTER VACCINE PROGRAMME FOR WINTER 2021 22

HSS(MD) 66 2021 - ADVICE ON THIRD PRIMARY DOSE FOR COVID-19 VACCINATION

HSS(MD)59 2021 Letter - UPDATED POLICY FOR MANAGEMENT OF SELF-ISOLATION OF CLOSE CONTACTS OF COVID-19 CASES WHO ARE FULLY VACCINATED – ADDITIONAL SAFEGUARDS FOR HEALTH AND SOCIAL CARE STAFF

HSS (MD) 52 2021 – CHANGE OF DOSE INTERVAL BETWEEN THE PFIZER-BIONTECH AND MODERNA COVID-19 VACCINES

20210723 Letter_Infection Prevention Control_ PHA_HSCB_RQIA

HSS MD 49 2021 – FULLY VACCINATED HEALTH & SOCIAL CARE STAFF TOLD TO SELF-ISOLATE AS A CLOSE CONTACT MAY BE PERMITTED TO ATTEND WORK IN EXCEPTIONAL CIRCUMSTANCES

HSS MD 47 2021 – PPE and Heat – Risk of Heat Stress

HSS (MD) 43 2021 UK PATIENT SAFETY ALERT NatPSA/2021/005/MHRA- Philips ventilator, CPAP and BiPAP devices

HSS (MD) 37 2021 VACCINATION PROTOCOL UPDATE FOR COVID-19 VACCINE ASTRAZENECA

HSS MD 35 2021 USE OF THE ASTRAZENECA VACCINE: ADVICE ON UPDATED JCVI STATEMENT

HSS(MD)32/2021 – VACCINATION PROTOCOL FOR COVID-19 VACCINE BNT162b2 (PFIZER / BIONTECH) AND UPDATE TO VACCINATION PROTOCOL FOR COVID-19 VACCINE ASTRAZENECA

HSS(MD) 31 2021 – END OF THE 2020 21 FLU SEASON AND RELATED ISSUES

HSS(MD) 28 2021 - COVID-19 VACCINE ASTRAZENECA AND THROMBOEMBOLIC EVENTS WITH CONCURRENT LOW PLATELET COUNTS

RQIA EU Settlement Scheme

Letter re Application of guidance document for NI 160221

Infection Prevention and Control Guidance January 2021

Dysphagia Booklet NHSCT for HSC Staff

A guide to COVID-19 vaccination - all women of childbearing age

HSS MD 92 2020 New variants of SARS-COV-2 Virus in South Africa; Action for the Health Service in Northern Ireland

HSS MD 3 2021 New variants of SARS-COV-2 Virus (Brazilian Variants); Action for the Health Service

HSS(MD) 74 202 Immediate Actions in Response to Mink-Variant Sars-Cov-2 Virus in Denmark

HSS MD 72 2020 THE HUMAN MEDICINES (CORONAVIRUS AND INFLUENZA) (AMENDMENT)

HSS MD 59 2020 - Seasonal Influenza Vaccination Programme 2020-21

Key Principles For Staff Visiting Community Settings

HSS MD 58 2020 - Use Of Face Masks/Face Covering In All Health And Social Care Facilities

HSS(MD)54-2020 - Personal Protective Equipment and Heat - Risk of Heat Stress

Letter re: Workforce movment – July 20

Reducing workforce movement between care homes – Final

HSS(MD)45/2020 - CARDIOPULMONARY RESUSCITATION (CPR), AS AN AEROSOL GENERATING PROCEDURE

HSSMD 38 2020 - COVID-19 CONTACT TRACING STRATEGY AND PROGRAMME IN NI

RP5282 – Letter to Chief Execs – Changes to Testing in Care Homes

PPE Community settings CNO PHA HSCB

HSS(MD)12 – 2020 – Message for all Clinical Staff encountering patients with respiratory infections arrived from overseas

SQR-SL-2020-060 (All PoCs) - Risk of Death or Serious Harm by Falling From A Hoist

HSS (MD) 9 2020 Covid 19 Becomes a Notifiable Disease in Northern Ireland

Policy for the identification of Invasive Medical Devices

Policy for the Identification and Labelling of Invasive Lines and Tubes

New Recommendations for Extreme caution required in relation to Yellow Fever Vacscine (STAMARIL)

FNFM Roadshow  Flyer – 22 August 2019

HSS(MD) 20 2019 - Seasonal Influenza Vaccination Programme 2019 2020

SQR SAI 2019-051 (ASPHC) - Delayed Diagnosis of DKA

HSS(MD) 4 2019 - Fluoroquinolone Antibiotics – New restrictions and precaustions

HSS(MD) 24 2018 - Adrenaline for anaphylaxis kits Reminder to Health Care Professionals

HSS(MD) 23 2018 - EpiPen and EpiPen_Junior (adrenalin Auto-injector devices)

CAS alert EpiPens final

Letter to Nursing Agencies 20/09/2018

PHC3 2018 Drug Alert Class  2 Medicines Recall Ventolin Accuhaler  200mcg

PHC4 2018 Drug Alert Class  2 Medicines Recall Ventolin Accuhaler  50/250mcg

HSC(SQSD) 118 Oxygen Cylinders

Guide to correct placement of labels - Appendix 2

Guide to correct placement of labels - Appendix 3

HSC(SQSD) 16 2018 Resources to support safer modification of food and drink